A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic Malignancies Treated with B-cell Targeting Chimeric Antigen Receptor T-Cell and T-Cell Redirecting Therapies

Secondary Immune Deficiency

Number of Serious Bacterial Infections (SBIs) per Participant The SBIs includes: bacteraemia / sepsis, bacterial meningitis, osteomyelitis / septic arthritis, bacterial pneumonia, and visceral abscess.

Number of Infections per Participant, Number CTCAE >= Grade 3 Infections per Participant. Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling limiting self-care activities of daily living. Infections of CTCAE Grade 3 or worse will be reported., Number of Days Hospitalized due to Infections, Number of Days With Anti-infectives Use, Number of Infection-related Deaths and Complications, Number of Infection-related Requirement for Intravenous (IV)Therapy, Number of Infection-related Requirement for Hospitalization per Participant, Number of Participants with TEAEs, Serious Adverse SAEs, AESIs, Infusion Site Reaction and Other Local Reactions. In this study, thromboembolic events are treated as AESIs., Trough Concentrations of Serum IgG, Area Under the Serum Concentration Time Curve (AUC) for IgG From Timepoint Zero to tau(AUC[0-t]), Maximal Serum Concentration (Cmax) of IgG, Time to Maximal Serum Concentration (Tmax) of IgG

No related papers found yet.